Business Context and Reporting Period
This Form 8-K was filed by Imprimis Pharmaceuticals, Inc. on April 13, 2017. The filing reports the entry into a Material Definitive Agreement with Cameron Ehlen Group, Inc. dba Precision Lens. The agreement establishes exclusive sales and marketing representation services for the Company's ophthalmic compounded formulation portfolio in select U.S. Midwest geographies.
Key Financial Metrics
The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses on the terms of a new commercial agreement rather than historical financial performance.
Material Changes and Agreement Terms
The primary material change is the execution of the Strategic Sales & Marketing Agreement. Key financial terms include:
- Commission Structure: Precision Lens receives a 10% commission on annual net sales of Products exceeding an initial threshold of $1,500,000 per calendar year.
- Stock Milestone Payments: The Company must issue restricted common stock upon reaching specific net sales thresholds:
- 10,000 shares if net sales reach $5,000,000 prior to December 31, 2017.
- 15,000 shares if net sales reach $5,000,000 (general threshold).
- 15,000 shares if net sales reach $10,000,000.
- 15,000 shares if net sales reach $15,000,000.
- 15,000 shares if net sales reach $20,000,000.
Outlook, Risks, and Contingencies
The agreement creates a contingent obligation for the Company to issue equity based on future sales performance. The filing does not provide specific management commentary on future financial guidance or identify new risks beyond the obligations inherent in the sales agreement. The full text of the agreement is filed as Exhibit 10.1.
Investor Verification Checklist
- Verify the exact definition of "Products" and "net sales" within Exhibit 10.1 to understand the scope of the commission and milestone triggers.
- Review the Company's current cash position and authorized share count to assess the impact of potential future stock issuances.
- Confirm the specific U.S. Midwest geographies covered by the exclusive representation to evaluate market expansion potential.
- Check for any existing agreements that might conflict with the exclusivity granted to Precision Lens.